AMGN - Amgen Inc Stock Price, Fair Value and News

269.42USD-3.59 (-1.31%)Market Closed

Market Summary

USD269.42-3.59

Market Closed

-1.31%

AMGN Stock Price

View Fullscreen

AMGN RSI Chart

AMGN Valuation

Market Cap

146.3B

Price/Earnings (Trailing)

21.78

Price/Sales (Trailing)

5.19

EV/EBITDA

13.41

Price/Free Cashflow

19.88

AMGN Price/Sales (Trailing)

AMGN Profitability

EBT Margin

27.86%

Return on Equity

107.78%

Return on Assets

6.91%

Free Cashflow Yield

5.03%

AMGN Fundamentals

AMGN Revenue

Revenue (TTM)

28.2B

Rev. Growth (Yr)

19.84%

Rev. Growth (Qtr)

18.73%

AMGN Earnings

Earnings (TTM)

6.7B

Earnings Growth (Yr)

-52.54%

Earnings Growth (Qtr)

-55.66%

Breaking Down AMGN Revenue

52 Week Range

211.71274.00

(Low)(High)

Last 7 days

3.4%

Last 30 days

-2.8%

Last 90 days

-12.0%

Trailing 12 Months

11.5%

How does AMGN drawdown profile look like?

AMGN Financial Health

Current Ratio

1.65

Debt/Equity

10.14

Debt/Cashflow

0.13

AMGN Investor Care

Dividend Yield

3.16%

Dividend/Share (TTM)

8.64

Shares Dilution (1Y)

0.36%

Diluted EPS (TTM)

12.5

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	26.2B	26.6B	26.8B	28.2B
2022	26.3B	26.4B	26.3B	26.3B
2021	25.2B	25.5B	25.8B	26.0B
2020	24.0B	24.3B	25.0B	25.4B
2019	23.8B	23.6B	23.4B	23.4B
2018	22.9B	23.2B	23.3B	23.7B
2017	22.9B	23.1B	23.0B	22.8B
2016	22.2B	22.5B	22.6B	23.0B
2015	20.6B	20.8B	21.5B	21.7B
2014	19.0B	19.5B	19.7B	20.1B
2013	17.5B	17.7B	18.1B	18.7B
2012	15.9B	16.4B	16.8B	17.3B
2011	15.2B	15.3B	15.4B	15.6B
2010	14.9B	15.0B	15.0B	15.1B
2009	14.7B	14.6B	14.6B	14.6B
2008	0	14.8B	14.9B	15.0B
2007	0	0	0	14.8B

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022

Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Amgen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 18, 2024	grygiel nancy a.	sold (taxes)	-189,016	268	-703	svp & cco
Mar 18, 2024	miller derek	sold (taxes)	-127,713	268	-475	svp, human resources
Mar 18, 2024	graham jonathan p	sold (taxes)	-1,580,690	268	-5,879	evp & gen. counsel & secy.
Mar 18, 2024	bradway robert a	sold (taxes)	-5,527,970	268	-20,560	chairman, ceo and president
Mar 18, 2024	santos esteban	sold (taxes)	-1,650,060	268	-6,137	evp, operations
Mar 18, 2024	reese david m	sold (taxes)	-1,667,530	268	-6,202	evp & chief technology officer
Mar 18, 2024	busch matthew c.	sold (taxes)	-39,255	268	-146	vp, finance & cao
Mar 18, 2024	gordon murdo	sold (taxes)	-1,737,170	268	-6,461	evp, global commercial ops
Mar 18, 2024	griffith peter h.	sold (taxes)	-1,389,520	268	-5,168	evp & cfo
Mar 18, 2024	khosla rachna	sold (taxes)	-117,765	268	-438	svp, business development

Which funds bought or sold AMGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	DeDora Capital, Inc.	added	22.05	256,567	1,509,290	0.48%
Apr 23, 2024	United Asset Strategies, Inc.	added	3.45	218,297	10,508,200	1.05%
Apr 23, 2024	Covenant Asset Management, LLC	added	5.45	56,052	1,425,010	0.23%
Apr 23, 2024	Shepherd Financial Partners LLC	reduced	-2.89	-17,745	411,285	0.05%
Apr 23, 2024	Global Retirement Partners, LLC	reduced	-20.73	-1,007,430	2,906,920	0.11%
Apr 23, 2024	PFG Private Wealth Management, LLC	added	5.23	5,339	143,013	0.09%
Apr 23, 2024	Principle Wealth Partners LLC	added	65.85	11,375,200	29,228,100	1.14%
Apr 23, 2024	Summit Trail Advisors, LLC	added	8.98	103,360	1,466,520	0.04%
Apr 23, 2024	WEDGE CAPITAL MANAGEMENT L L P/NC	reduced	-99.21	-31,013,700	244,515	-%
Apr 23, 2024	Walkner Condon Financial Advisors LLC	reduced	-0.83	-8,676	409,776	0.09%

Are Funds Buying or Selling AMGN?

Are funds buying AMGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AMGN

No. of Funds

Unveiling Amgen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.16%	49,036,311	SC 13G/A
Jan 30, 2024	state street corp	5.52%	29,543,705	SC 13G/A
Jan 25, 2024	blackrock inc.	8.9%	47,811,356	SC 13G/A
Feb 09, 2023	vanguard group inc	9.01%	48,065,139	SC 13G/A
Feb 07, 2023	blackrock inc.	9.1%	48,513,079	SC 13G/A
Feb 06, 2023	state street corp	5.58%	29,760,088	SC 13G/A
Feb 11, 2022	capital research global investors	3.9%	22,157,906	SC 13G/A
Feb 10, 2022	state street corp	5.37%	30,221,708	SC 13G/A
Feb 09, 2022	vanguard group inc	8.28%	46,661,009	SC 13G/A
Feb 01, 2022	blackrock inc.	8.9%	50,046,345	SC 13G/A

Recent SEC filings of Amgen Inc

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	DEFA14A	DEFA14A
Apr 10, 2024	ARS	ARS
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to Amgen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	357.8B	85.2B	-4.29%	-10.06%	10.18	4.2	6.46%	95.94%
MRK	321.7B	60.1B	1.36%	9.00%	881.36	5.35	1.40%	-97.49%
PFE	148.3B	46.5B	-4.27%	-33.23%	-106.79	3.19	42.59%	-114.62%
AMGN	146.3B	28.2B	-2.78%	11.49%	21.78	5.19	7.09%	2.52%
GILD	83.6B	27.1B	-7.58%	-21.63%	14.75	3.08	-0.60%	23.36%
TEVA	14.6B	15.8B	-7.47%	58.08%	-25.3	0.92	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	0.71%	-13.71%	-333.24	0.91	4.58%	90.97%
ALKS	4.1B	1.7B	-9.74%	-19.21%	11.58	2.48	49.61%	324.78%
BHC	3.1B	8.8B	-9.70%	20.22%	-5.28	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-6.03%	4.38%	14.34	3.06	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-14.42%	-17.86%	-4.05	1.92	24.65%	80.36%
TXMD	22.3M	1.3M	-15.72%	-46.54%	-2.17	17.09	-98.14%	-109.18%
ACRX	16.3M	-	-17.24%	40.47%	-0.89	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	-33.33%	-94.15%	-0.19	0.14	80.00%	43.08%
ACOR	683.2K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Amgen Inc News

Latest updates

Amgen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	18.7%	8,196	6,903	6,986	6,105	6,839	6,652	6,594	6,238	6,846	6,706	6,526	5,901	6,634	6,423	6,206	6,161	6,197	5,737	5,871	5,557	6,230
Costs and Expenses	41.8%	6,925	4,882	4,302	4,184	4,609	3,992	4,418	3,738	4,542	4,328	5,698	3,772	4,626	3,970	3,883	3,806	4,149	3,261	3,193	3,085	3,848
S&GA Expenses	68.1%	2,274	1,353	1,294	1,258	1,572	1,287	1,327	1,228	1,425	1,305	1,384	1,254	1,773	1,346	1,295	1,316	1,513	1,223	1,260	1,154	1,559
EBITDA Margin	-4.9%	0.53*	0.55*	0.56*	0.54*	0.46*	0.47*	0.46*	0.42*	0.43*	0.43*	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	8.2%	821	759	752	543	415	368	328	295	335	296	281	285	318	302	296	346	301	313	332	343	352
Income Taxes	-60.8%	85.00	217	235	601	132	249	214	199	232	271	94.00	211	262	185	227	195	280	309	385	322	257
Earnings Before Taxes	-56.2%	852	1,947	1,614	3,442	1,748	2,392	1,531	1,675	2,131	2,155	558	1,857	1,877	2,206	2,030	2,020	1,983	2,277	2,564	2,314	2,185
EBT Margin	-14.6%	0.28*	0.33*	0.35*	0.35*	0.28*	0.29*	0.28*	0.25*	0.26*	0.25*	-	-	-	-	-	-	-	-	-	-	-
Net Income	-55.7%	767	1,730	1,379	2,841	1,616	2,143	1,317	1,476	1,899	1,884	464	1,646	1,615	2,021	1,803	1,825	1,703	1,968	2,179	1,992	1,928
Net Income Margin	-15.5%	0.24*	0.28*	0.30*	0.30*	0.25*	0.26*	0.25*	0.22*	0.23*	0.22*	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-88.5%	289	2,512	3,838	720	2,309	2,818	1,684	1,974	2,521	2,176	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	7.3%	97,154	90,534	90,269	88,720	65,121	63,700	59,294	59,196	61,165	64,993	59,773	62,539	62,948	64,637	65,011	61,669	59,707	59,535	59,373	63,997	66,416
Current Assets	-37.4%	30,332	48,477	47,380	44,703	22,186	24,062	19,322	18,520	19,385	24,380	19,099	21,299	21,144	22,661	22,895	18,813	18,440	31,051	30,746	35,151	37,618
Cash Equivalents	-68.5%	10,944	34,700	34,200	31,600	7,629	9,502	5,203	6,528	7,989	11,969	6,630	6,112	6,266	9,087	9,145	7,687	6,037	11,415	5,525	7,358	6,945
Inventory	89.4%	9,518	5,026	4,978	5,011	4,930	4,757	4,554	4,411	4,086	4,152	4,115	4,017	3,893	3,942	3,840	3,682	3,584	3,243	3,176	3,016	2,940
Net PPE	6.8%	5,941	5,563	5,532	5,460	5,427	5,188	5,158	5,142	5,184	4,982	4,906	4,855	4,889	4,816	4,843	4,879	4,928	4,901	4,882	4,892	4,958
Goodwill	498.8%	18,629	3,111	15,531	15,531	15,529	14,845	14,865	14,897	14,890	14,665	14,676	14,673	14,689	14,674	14,678	14,683	14,703	14,705	26.00	14,692	14,699
Current Liabilities	8.5%	18,392	16,954	17,097	14,215	15,687	14,331	12,618	12,886	12,184	14,842	14,585	12,869	11,653	9,953	10,523	11,827	12,835	10,737	10,622	12,706	13,488
Long Term Debt	7.0%	63,170	59,040	59,377	60,761	37,354	37,161	35,705	36,010	33,222	33,291	28,458	31,129	32,895	34,196	34,133	30,008	26,950	27,742	27,798	29,319	29,510
LT Debt, Current	1.1%	1,443	1,428	2,167	834	1,591	1,543	817	844	87.00	4,288	4,324	1,556	91.00	91.00	91.00	1,840	2,953	2,049	2,816	3,705	4,419
LT Debt, Non Current	7.0%	63,170	59,040	59,377	60,761	37,354	37,161	35,705	36,010	33,222	33,291	28,458	31,129	32,895	34,196	34,133	30,008	26,950	27,742	27,798	29,319	29,510
Shareholder's Equity	-18.6%	6,232	7,656	6,781	5,348	3,661	3,653	2,419	916	6,700	8,217	8,247	9,334	9,409	10,959	10,659	9,485	9,673	10,927	10,794	10,832	12,500
Retained Earnings	-6.3%	-26,549	-24,971	-25,540	-26,919	-28,622	-28,066	-28,252	-29,568	-24,600	-22,964	-22,762	-21,639	-21,408	-19,851	-20,168	-21,378	-21,330	-20,136	-20,054	-19,895	-17,977
Shares Outstanding	0.1%	535	535	535	534	534	539	535	548	570	567	575	577	-	-	-	-	-	-	-	-	-
Float	-	-	-	118,556	-	-	-	129,940	-	-	-	137,531	-	-	-	138,057	-	-	-	110,809	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-80.5%	538	2,760	4,109	1,064	2,649	2,978	1,930	2,164	2,808	2,418	1,931	2,104	2,153	3,368	2,842	2,134	2,514	3,377	1,414	1,845	3,194
Share Based Compensation	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	87.00
Cashflow From Investing	-10239.3%	-27,089	-262	-211	1,358	-3,473	-267	-2,193	-111	-230	73.00	1,209	-319	-1,384	-1,628	-2,159	-230	-5,963	5,372	2,745	3,555	-4,637
Cashflow From Financing	237.4%	2,754	-2,005	-1,210	21,509	-1,049	1,588	-1,062	-3,514	-6,558	2,848	-2,622	-1,939	-3,590	-1,798	775	-254	-1,929	-2,859	-5,992	-4,987	-3,568
Dividend Payments	0%	1,140	1,140	1,139	1,137	1,040	1,038	1,038	1,080	990	999	1,008	1,016	932	936	942	945	860	868	880	901	840
Buy Backs	-	-	-	-	-	900	-	50.00	6,310	1,446	1,069	1,592	865	1,208	752	591	933	1,123	1,170	2,349	3,031	2,114

AMGN Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenues	$ 28,190	$ 26,323	$ 25,979
Operating expenses:
Cost of sales	8,451	6,406	6,454
Research and development	4,784	4,434	4,819
Acquired in-process research and development	0	0	1,505
Selling, general and administrative	6,179	5,414	5,368
Other	879	503	194
Total operating expenses	20,293	16,757	18,340
Operating income	7,897	9,566	7,639
Other income (expense):
Interest expense, net	(2,875)	(1,406)	(1,197)
Other income (expense), net	2,833	(814)	259
Income before income taxes	7,855	7,346	6,701
Provision for income taxes	1,138	794	808
Net income	$ 6,717	$ 6,552	$ 5,893
Earnings per share:
Basic (in usd per share)	$ 12.56	$ 12.18	$ 10.34
Diluted (in usd per share)	$ 12.49	$ 12.11	$ 10.28
Shares used in the calculation of earnings per share:
Basic (in shares)	535	538	570
Diluted (in shares)	538	541	573
Product sales
Revenues:
Total revenues	$ 26,910	$ 24,801	$ 24,297
Other revenues
Revenues:
Total revenues	$ 1,280	$ 1,522	$ 1,682

AMGN Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 10,944	$ 7,629
Marketable securities	0	1,676
Trade receivables, net	7,268	5,563
Inventories	9,518	4,930
Other current assets	2,602	2,388
Total current assets	30,332	22,186
Property, plant and equipment, net	5,941	5,427
Intangible assets, net	32,641	16,080
Goodwill	18,629	15,529
Other noncurrent assets	9,611	5,899
Total assets	97,154	65,121
Current liabilities:
Accounts payable	1,590	1,572
Accrued liabilities	15,359	12,524
Current portion of long-term debt	1,443	1,591
Total current liabilities	18,392	15,687
Long-term debt	63,170	37,354
Long-term deferred tax liabilities	2,354	11
Long-term tax liabilities	4,680	5,757
Other noncurrent liabilities	2,326	2,651
Contingencies and commitments
Stockholders’ equity:
Common stock and additional paid-in capital; $0.0001 par value per share; 2,750.0 shares authorized; outstanding—535.4 shares in 2023 and 534.0 shares in 2022	33,070	32,514
Accumulated deficit	(26,549)	(28,622)
Accumulated other comprehensive loss	(289)	(231)
Total stockholders’ equity	6,232	3,661
Total liabilities and stockholders’ equity	$ 97,154	$ 65,121

About Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with BehÃƒÂ§et's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

CEO	Mr. Robert A. Bradway
WEBSITE	amgen.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	25200

Amgen Inc Frequently Asked Questions

What is the ticker symbol for Amgen Inc? What does AMGN stand for in stocks?

AMGN is the stock ticker symbol of Amgen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amgen Inc (AMGN)?

As of Wed Apr 24 2024, market cap of Amgen Inc is 146.31 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers.

What is the fair value of AMGN stock?

You can check AMGN's fair value in chart for subscribers. The fair value of Amgen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amgen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amgen Inc a good stock to buy?

The fair value guage provides a quick view whether AMGN is over valued or under valued. Whether Amgen Inc is cheap or expensive depends on the assumptions which impact Amgen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMGN.

What is Amgen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 24 2024, AMGN's PE ratio (Price to Earnings) is 21.78 and Price to Sales (PS) ratio is 5.19. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMGN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Amgen Inc's stock?

In the past 10 years, Amgen Inc has provided 0.122 (multiply by 100 for percentage) rate of return.